Compare Davita Inc (DVA) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Herbalife Nutrition Ltd — how do they compare? Davita Inc trades at $179.12 (market cap $11.38B), while Herbalife Nutrition Ltd trades at $11.71 (market cap $1.23B). The key difference: Davita Inc is far larger — about 9.3× Herbalife Nutrition Ltd's market cap, and Davita Inc is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals.
| DVA | HLF | |
|---|---|---|
Market Cap | $11.38B | $1.23B |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $19.96 |
52-Week Low | $103.87 | $7.75 |
Enterprise Value | $24.10B | $3.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
HLF trades at $11.52, down 6.72% in the past 24 hours, with a bearish technical signal and mixed earnings history. The company reported Q2 2026 net sales of $1.3 billion, up 5.4% year-over-year, but missed EPS estimates. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24, though negative shareholder equity and high debt levels remain concerns. Recent news includes a planned CFO transition in December 2026 and inclusion in TIME's America's Best Companies list.
The outlook is cautious due to inconsistent earnings performance and a highly leveraged balance sheet, but low valuation metrics and analyst consensus leaning buy (53.84%) suggest potential upside if operational improvements and debt reduction continue. Key risks include execution challenges, competitive pressures, and sensitivity to macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
